Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China

• Main Authors: Peng-Le Guo (Author), Hao-Lan He (Author), Xie-Jie Chen (Author), Jin-Feng Chen (Author), Xiao-Ting Chen (Author), Yun Lan (Author), Jian Wang (Author), Pei-Shan Du (Author), Huo-Lin Zhong (Author), Hong Li (Author), Cong Liu (Author), Li-Ya Li (Author), Feng-Yu Hu (Author), Xiao-Ping Tang (Author), Wei-Ping Cai (Author), Ling-Hua Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dual therapy with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) has been demonstrated to be non-inferior to the triple drug regimen including LPV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) in 48-week studies. However, little is known about the long-term efficacy and drug resi...